Short and Optimal Duration of Dual Antiplatelet Therapy Study
NCT01659034
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
1525
Enrollment
OTHER
Sponsor class
Conditions
Coronary Artery Disease
Interventions
DRUG:
Thienopyridine for 3 months
Sponsor
Takeshi Morimoto